{
    "clinical_study": {
        "@rank": "153167", 
        "arm_group": [
            {
                "arm_group_label": "resveratrol", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "corn starch", 
                "arm_group_type": "Placebo Comparator", 
                "description": "(10 patients) 100mg 2x/day\n1 month"
            }
        ], 
        "brief_summary": {
            "textblock": "Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters\n      in patients with schizophrenia taking antipsychotics?"
        }, 
        "brief_title": "Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "Randomized, double-blind, placebo-controlled trial comparing supplementation with\n      resveratrol or placebo in patients diagnosed with schizophrenia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which\n        are in clozapine medication for at least 6 months.\n\n        Exclusion Criteria:\n\n        Patients will be excluded from the study:\n\n          -  Have a diagnosis of diabetes\n\n          -  Use other antipsychotic drugs, clozapine beyond\n\n          -  Using medicines for diabetes or dyslipidaemia\n\n          -  Accept not participate in any stage of the research."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062190", 
            "org_study_id": "RESV-110553", 
            "secondary_id": "ufrgs110553"
        }, 
        "intervention": {
            "arm_group_label": "resveratrol", 
            "description": "100mg 2x/day\n1 month", 
            "intervention_name": "resveratrol", 
            "intervention_type": "Drug", 
            "other_name": [
                "Resveratrol (10 patients)", 
                "Placebo (10 patients)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "karine.personaldiet@gmail.com", 
                "last_name": "Karine Zort\u00e9a, MD", 
                "phone": "84296901"
            }, 
            "facility": {
                "address": {
                    "city": "Porto Alegre", 
                    "country": "Brazil", 
                    "state": "RS", 
                    "zip": "90035-903"
                }, 
                "name": "HCPA"
            }, 
            "investigator": {
                "last_name": "Karine Zort\u00e9a, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal", 
        "other_outcome": {
            "description": "Nutritional evaluation will be conducted by anthropometric data (weight, height, waist and hip circumference, body fat percentage) and food intake by 24-hour Recall Survey (24HR).", 
            "measure": "Nutritional evaluation will be conducted by anthropometric data and food intake by 24-hour Recall Survey.", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "overall_contact": {
            "email": "karine.persobnaldiet@gmail.com", 
            "last_name": "Karine Zort\u00e9a"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Brazil: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of cardiovascular risk will be realized by measurement of cytokine levels (IL-12p70, IL-6, IL-10, IL-1b, IL-8 and TNF-\u03b1), C-reactive protein and cholesterol levels (total cholesterol, LDL, HDL, triglycerides) in patients with schizophrenia before and after supplementation with resveratrol or placebo.", 
            "measure": "Assessment of cardiovascular risk will be realized by measurement of cytokine levels, C-reactive protein and cholesterol levels.", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062190"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of Rio Grande do Sul", 
            "investigator_full_name": "Karine Zort\u00e9a", 
            "investigator_title": "Master", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Cognitive performance will be assessed with a battery of cognitive tests (Hopkins, for verbal memory; Stroop: for executive function; Digits WAIS-III, for attention; and Sequence numbers and letters for verbal memory and attention) and BPRS  (brief psychiatric rating scale) to assess symptoms.", 
            "measure": "Cognitive performance will be assessed with a battery of cognitive tests and BPRS  (brief psychiatric rating scale) to assess symptoms.", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "source": "Federal University of Rio Grande do Sul", 
        "sponsors": {
            "collaborator": {
                "agency": "Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Federal University of Rio Grande do Sul", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}